Activating mutations in the KRAS gene are present in more than 80% of pancreatic cancers and more than 30% of colorectal cancers (Timar and Kashofer, 2020) and have been shown to be significantly associated with the poor prognosis of many cancers, such as pancreatic cancer (Buscail et al., 2020) and non-small cell lung cancer (Cai et al., 2020). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.